UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 27, 2026
InspireMD, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-35731 | 26-2123838 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
6303 Waterford District Drive, Suite 215 Miami, Florida 33126 | 6744832 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (888) 776-6804
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
| Common Stock, $0.0001 par value per share | NSPR | The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 27, 2026, InspireMD, Inc. (the “Company”) provided a notice of dismissal to Andrea Tommasoli, the Company’s Chief Operating Officer.
Mr. Tommasoli is employed by InspireMD Ltd., a wholly owned subsidiary of the Company, pursuant to an Employment Contract, dated November 2, 2020, governed by French law (the “Employment Agreement”). The termination of Mr. Tommasoli’s employment is subject to a six-month notice period for dismissal under the Employment Agreement, as well as compliance with applicable French labor laws. Mr. Tommasoli has been released from his duties effective April 1, 2026, but will continue to receive his base salary through the end of the notice period and will continue to receive health and provident benefits under applicable French Law for a maximum of 12 months. Mr. Tommasoli will also be entitled to severance pay in the amount of approximately €61,000 gross and total cost plus the balance of any accrued and untaken paid leave.
Subject to compliance with applicable French law, Mr. Tommasoli’s last day of employment with the Company is expected to be September 1, 2026.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number | Description | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INSPIREMD, INC. | |||
| Date: | March 4, 2026 | By: | /s/ Marvin Slosman |
Name: Title: | Marvin Slosman Chief Executive Officer | ||